Back to mobile site

Kura Oncology (KURA) Reiterated at Market Outperform by Citizens After Q4 Results

March 6, 2026 4:49 AM EST Send to a Friend
Citizens analyst Reni J. Benjamin reiterated a Market Outperform rating and $24.00 price target on Kura Oncology (NASDAQ: KURA).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login